The FDA pushed back review timelines for Eylea HD, classifying the submission as a major amendment, while Novo Nordisk acquired the manufacturer.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Regeneron Pharmaceuticals →

  American pharmaceutical company

  • Regeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.Sun 14:10
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08

Related events

• Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Sep 3
• The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.Sep 22
• Data was presented in Athens supporting a future U.S. NDA submission to the FDA.Sep 4
• Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.Sep 2
• Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Jun 8